FILTER
LATEST INTERVIEWS
David Cory
CEO, EIGER BIOPHARMACEUTICALS
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.
Barbara Weber
CEO, TANGO THERAPEUTICS
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Ángel Tobar
GENERAL MANAGER ANDEAN REGION, EPIROC
"Battery-charging technologies should be used in a similar way to cellphones, regardless of the brand"
Eduardo Denyer Angel
PRESIDENT, BRENNTAG LATIN AMERICA NORTH
Brenntag is growing rapidly in Mexico through aquistions and increasing market share and penetration.
Michael Bigham & Evan Loh
PARATEK PHARMACEUTICALS
Paratek focuses on drugs that target infectious disease and other difficult-to-treat conditions.
Fernando Gutiérrez
PRESIDENT, MEXICAN COLLEGE OF CIVIL ENGINEERS (CICM)
Mexico is upgrading its infrastructure, offering opportunities for steel producers and construction firms alike.
David Kelley
PRESIDENT AND CEO, CHAKANA COPPER
Chakana Copper recently listed on the TSX and is busy exploring its acquisition in Peru, the Soledad project.
Gorden Glenn
CHAIRMAN, PRESIDENT AND CEO, MINNOVA CORP.
Minnova explains to GBR how it is planning to speedily bring to production its PL gold mine in Manitoba.
Richard Pino
VICE PRESIDENT SALES AND MARKETING, LATIN AMERICA, CRODA DO BRASIL
Recent acquisitions and investments have considerably enlarged Croda's presence in Brazil both in manufacturing and in R&D with its new innovation center at Campinas.
Richard Peters
PRESIDENT AND CEO, MERRIMACK PHARMACEUTICALS
Merrimack Pharmaceuticals is focused on cancer treatment through a deeper understanding of cancer pathways and biological markers.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
MACIG 2025 - Mining in Africa Country Investment Guide
It is said that mining is a patient industry. Current demand projections are not. Demand for minerals deemed ‘critical’ is set to increase almost fourfold by 2030, according to the UN. Demand for nickel, cobalt and lithium is predicted to double, triple and rise ten-fold, respectively, between 2022 and 2050. The world will need to mine more copper between 2018 and 2050 than it has mined throughout history. 2050 is also the deadline to curb emissions before reaching a point of ‘no return.’ The pace of mineral demand and the consequences of not meeting it force the industry to act fast and take more risks. Mining cannot afford to be a patient industry anymore. The scramble for supply drives miners back to geological credentials, and therefore to places like the African Central Copperbelt.
It is said that mining is a patient industry. Current demand projections are not. Demand for minerals deemed ‘critical’ is set to increase almost fourfold by 2030, according to the UN. Demand for nickel, cobalt and lithium is predicted to double, triple and rise ten-fold, respectively, between 2022 and 2050. The world will need to mine more copper between 2018 and 2050 than it has mined throughout history. 2050 is also the deadline to curb emissions before reaching a point of ‘no return.’ The pace of mineral demand and the consequences of not meeting it force the industry to act fast and take more risks. Mining cannot afford to be a patient industry anymore. The scramble for supply drives miners back to geological credentials, and therefore to places like the African Central Copperbelt.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
